In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PEOPLE - HealthSouth elects to the board:

This article was originally published in Clinica

Executive Summary

Surgery, imaging and patient services provider HealthSouth (Birmingham, Alabama) has elected Yvonne Curl to its board of directors, effective immediately. Ms Curl was previously the chief marketing officer of communications solutions firm Avaya. Prior to that, she served for Xerox for almost 25 years, holding positions in sales, marketing and field operations.

You may also be interested in...



Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.

Approval Of Medtronic’s Renal Denervation System Delayed By COVID-19

Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.

ACC 2020: SPYRAL HTN-OFF MED Results Support Medtronic’s Renal Denervation System

Three-month results of the SPYRAL HTN-OFF MED pivotal trial show renal denervation with Medtronic’s Symplicity Spyral system significantly reduced blood pressure in hypertensive patients not taking anti-hypertensive medications.

Topics

UsernamePublicRestriction

Register

MT060281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel